Straight Lines Consultancy

Bella's Story PharmAust

Beagle “Louie” was given 4-8 weeks to live but has surpassed 240 days (8 months) on PharmAust’s MPL treatment, and is enjoying an excellent quality of life!

🐶🐶🐶

Louie the beagle beating the odds thanks to PharmAust’s canine cancer trial Sponsored content

Pet Dog Monepantel Trial: Owners will have to transport their dogs to their respective centres and pay the cost of the initial consultation for diagnosis. Once the pet is diagnosed with lymphoma, PharmAust will cover all clinical trial costs, including travel expenses to and from the trial centre as well as post-trial mainte...

PharmAust will now be able to report on the progression of the disease earlier. Good results will see the company expedite into an MND/ALS Phase 2 trial.

The MND/ALS market is approximately $3.6b in annual sales. The current standard of care is Riluzole with sales of $1bn per year.

PharmAust’s interim analysis could set the stage for expedited Phase-2 MND trial - Stockhead PharmAust is looking to expedite the start of Phase-2 clinical trials of its lead drug monepantel for the treatment of Motor Neurone Disease.

Current standard of care (palliative steroid therapy) typically provides for 6-8 week survival in association with a range of adverse events… Louie is into his 32nd week of MPL therapy and is happily wagging his tail with no side effects!! 🐶🐶🐶

Learn more about PharmAust's MPL trial for dogs with B Cell Lymphoma here https://www.pharmaust.com/petdogtrial/

Cancer trial not a cure, but could prolong Bella's life and help other dogs 'I wanted to do the program to prolong the event result and give Bella the best life, while...

PharmAust and FightMND band together to fight against Motor Neurone Disease

PharmAust and FightMND band together to fight against Motor Neurone Disease - Stockhead FightMND’s annual Big Freeze event will be held during the AFL match between Collingwood and Melbourne at the MCG on June 13th.

“HAULIN' OATS” - Oat Pale Ale 🍺

A Rocky Ridge Brewing Co collaboration with Dirty Clean Food

$WOA/Wide Open Agriculture is a West Aussie food company that’s putting saving the planet on the menu

Drink beer and help save the planet 🌎

HAULIN' OATS | OAT PALE ALE HAULIN' OATS A Collaboration with Dirty Clean Food Oat Pale Ale | 5% Dirty Clean Food is a West Aussie food company that’s putting saving the planet on the menu. Our clean, rolled oats used for Rocky Ridge’s latest beer offering are grown by West Aussie farmers in the Wheatbelt. They are farmed ...

Takeoff for Structural Monitoring Systems: Shares surge ~55% on US approval for its tech to detect aircraft cracks

https://stockhead.com.au/news/takeoff-for-structural-monitoring-systems-shares-surge-55-on-us-approval-for-tech-to-detect-aircraft-cracks/

Takeoff for Structural Monitoring Systems: Shares surge ~55% on US approval for its tech to detect aircraft cracks - Stockhead Shares in Structural Monitoring System (ASX:SMN) are up ~55% to $1.06 with US approval for their CVM sensor technology detecting cracks in aircraft.

Certified Carbon Neutral OatUP is a dairy free milk alternative, helping you squeeze every last drop of goodness out of your day. It is the only plant-based milk in the world that is carbon-neutral certified and made using Western Australian (WA) oats.

Wide Open Agriculture signs oat milk distribution deal with Woolworths Wide Open Agriculture (ASX: WOA) has secured its largest distribution deal to date, locking in supermarket giant Woolworths Group (ASX: WOW) as a supplier

WOA is pleased to release its Quarterly results for Q4 FY21 and Appendix 4C cash flow statement, highlighting the eighth straight quarter of revenue growth. Managing Director, Dr Ben Cole said "our commercial strategy is working. We have again managed to grow our revenue base while simultaneously launching new products and undertaking significant research and development programs that are expected to add long term company value. As our revenue and reach grows, so too does our regenerative impact."

View the full quarterly report presentation below.
https://www.wideopenagriculture.com.au/sites/default/files/asx-announcements/61042752.pdf

While the focus has been largely on vaccines, PharmAust is trialling a pill that directly targets SARS-CoV-2. Today’s results are the next step towards a human clinical trial

https://stockhead.com.au/health/pharmausts-pill-significantly-protects-against-covid-19-virus/

PharmAust’s pill significantly protects against COVID-19 virus - Stockhead While the focus has been largely on vaccines, PharmAust is trialling a pill that directly targets SARS-CoV-2. Today’s results are the next step.

PharmAust delivers breakthrough in canine cancer fight ASX-listed PharmAust appears to have made a breakthrough in its fight to combat canine cancer with a “phase IIb” trial of its Monepantel anti-cancer drug reportedly achieving tumour regression and increased progression-free survival in dogs. The company says the results could have significant im...

PharmAust receives ethics approval just in time for Big Freeze - The Sentiment There is nothing fun about plunging into freezing cold ice water during a cold Melbourne winter. However, each year, bold celebrities participate in the annual ‘Big Freeze’ at the Melbourne Cricket Ground before the Melbourne vs Collingwood AFL clash on the Queen’s Birthday weekend. The event,...

PharmAust secures ethics approval, prepares for clinical trial of MPL in patients with motor neurone disease After securing ethics approval, PharmAust (ASX: PAA) is gearing up to begin a phase I clinical trial in the December quarter, which will assess its monepantel drug in patients with motor neurone disease.

WOA is pleased to announce that following a three-month intensive research program led by Curtin University and food scientist and co-inventor of the lupin technology, Dr Stuart Johnson, a number of early-stage food and drink prototypes have successfully been developed using WOA’s Modified Lupin Protein (MLP) concentrate.

This marks the most significant milestone in the Company’s lupin project to date and is a major step towards confirming the commercial viability of using MLP across multiple plant-based food and beverage sectors.
https://www.wideopenagriculture.com.au/sites/default/files/asx-announcements/61034522.pdf

Have you recently diagnosed lymphoma in a dog? Has the client declined chemotherapy or is undecided?

The Pet Oncologist and Veterinary Specialist Services, in partnership with PharmAust, are enrolling dogs with B-cell lymphoma in a clinical trial investigating a novel oral cancer medication. All diagnostic and treatment costs are covered in this study, with the initial consultation cost borne by the client. Participants are enrolled in the trial for a month.

Dogs may be eligible for the trial if they:
• Have not been pre-treated with chemotherapy
• Have B-cell multicentric lymphoma
• Are well enough to survive the duration of the trial (4 weeks)
• Weigh more than 11 kg

Interested owners can schedule to see Dr. Catherine Chan (Veterinary Oncologist) at Veterinary Specialist Services, Underwood on (07) 3841 7011. For further information, please email [email protected].

Has your dog recently been diagnosed lymphoma?

Perth Veterinary Specialists, in partnership with PharmAust, are enrolling dogs with B-cell lymphoma in a clinical trial investigating a novel oral cancer medication. All diagnostic and treatment costs are covered in this study. Participants are enrolled in the trial for a month.

Dogs may be eligible for the trial if they:
• Have not been pre-treated with chemotherapy or steroids
• Have B-cell multicentric lymphoma
• Are well enough to survive the duration of the trial (4 weeks)
• Weigh more than 11 kg

Interested owners can schedule an initial
consultation with Dr. Jessica Finlay (Veterinary Oncologist), Dr Ken Wyatt (Veterinary Oncologist), Dr. Sarah Mitchell (Oncology Registrar) or Dr. Albert Thomas (Oncology Resident) at Perth Veterinary Specialists. Call (08) 9204 0400 or for further information, and (or) please email [email protected]

WOA is pleased to announce that its plant-based milk product, OatUP, has been certified “Carbon Neutral” by , the Australian government backed initiative for climate action. .au will now become the world’s first Carbon Neutral oat milk product, with its production and sales equating to zero net greenhouse gas emissions. Find out more at oatup.com.au
https://www.wideopenagriculture.com.au/sites/default/files/asx-announcements/61003386.pdf

Great opportunity for an inspiring and passionate barista-trained Brand Ambassador with great technical oat milk/coffee and training skills. Must have a good knowledge of the Perth café scene, knowledge of the most influential cafes / baristas in town, and established relationships with cafes in Perth.

https://regenfarming.news/jobs/d/743-brand-ambassador-wide-open-agriculture

Brand Ambassador | Wide Open Agriculture At Wide Open Agriculture (WOA), we are reinventing the way the world grows, thinks about and buys food to create a better future for people a...

PharmAust sets strategy for multipurpose drug Perth based oncology company, PharmAust, has confirmed the anti-viral potential of its Monepantel drug in the fight against COVID-19 and firmed up its strategy for other potential treatments using the drug, including treating cancer in dogs and treating human neurodegenerative disease.

PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer

https://smallcaps.com.au/pharmaust-clinical-trials-monepantel-fights-covid-19-infectivity-canines-cancer/

PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer Clinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter performance to lead drug monepantel and monepantel sulfone which has shown “remarkable” early results against COVID-19 infections.

PHARMAUST RECRUITS MORE RESEARCHERS FOR DOG CANCER TRIAL

cWA Comment: Especially for all our dog lover Warriors

PharmAust (PAA) has signed on some important researchers for its Phase II dog cancer trial.

The trial is designed to treat pet dogs with lymphoma. Phase I showed some positive results, and now PharmAust has recruited the University Veterinary Teaching Hospital of Sydney (UVTHS) and the West Australian Veterinary Emergency and Specialists (WAVES) to lend their expertise.

Dr Peter Bennett, a renowned cancer clinical trial specialist, will run the UVTHS site. Dr Sue Bennett, an internal medicine specialist with a particular focus on urinary, respiratory and immunological diseases, will run the WAVES site.

The doctors are not related.

PharmAust Chief Scientific Officer Dr Richard Mollar said the company is excited to bring the two Dr Bennetts on board.

"Having the participation of such highly accredited veterinarians and hospitals is a tribute to the diligent preclinical and clinical work PharmAust has executed preparing monepantel for re-entry into the clinic for this pivotal trial," Dr Richard said.

The trial focuses on PharmAust's monepantel (MPL) drug, which was shown to be well-tolerated in both humans and dogs in Phase I of the trial.

The drug is designed to inhibit the mTOR pathway which, according to PharmAust, is a key driver of lymphoma.

With the two new research sites, PhamAust now has central referral sites in Victoria, New South Wales, and Western Australia.